prof. dr. Alain van Gool PhD

About Alain van Gool

Alain van Gool is professor Personalized Healthcare at the Radboud university medical center, with a strong passion in the application of biomarkers in translational medicine and personalized healthcare. After his study (biochemistry, 1991) and PhD (molecular biology, 1996) Alain worked at a mix of academia, pharmaceutical industries, applied research institutes, university medical centers in Europe, Asia and USA. He has been leading technology-based biomarker laboratories, cross-functional expert teams, therapeutic project teams and public-private consortia, many of which were focused on the discovery, development and implementation of translational biomarkers in a variety of therapeutic areas. His technical expertise resides most strongly in molecular profiling (various Omics approaches), analytical biomarker development and applications in translational scientific research.

Alain thrives to work with specialists to translate basic research to applied science and clinical impact. He coordinates several biomarker/omics/data programs as part of the Translational Metabolic Laboratory including Project leader and PI of the Netherlands X-omics Initiative, is Strategic Advisor to the Executive Board of Radboudumc, co-coordinates the Radboudumc Technology Centers, is Scientific Lead Technologies of DTL (the Dutch Techcenter for Life Sciences), is Chair Biomarker Platform of EATRIS (the European infrastructure for Translational Medicine), is co-initiator of Health-RI (the Netherlands Health Research Infrastructure for Personalized Medicine and Health), thus contributing to the organisation and coordination of local, national and European technology infrastructures. Complementing his daily work, he enjoys contributing to scientific advisory boards of start-up enterpreneurs, multinational companies, translational organisations, funding agencies and conference organisers.

Alain currently heads the 100 fte Translational Metabolic Laboratory of the Radboudumc, a mixed function research-diagnostic lab that specializes in genetic metabolic disorders and includes the Radboudumc proteomics, glycomics & metabolomics platforms. He also coordinates the Radboudumc Technology Centers, is Scientific Lead Technologies of DTL (the Dutch Techcenter for Life Sciences), is co-initiator of Health-RI (the Netherlands Personalised Medicine and Health Research Infrastructure), is PI of the Biomarker Development Center and is chair Biomarker Platform of EATRIS (the European infrastructure for Translational Medicine, thus contributing to the organization and coordination of local, national and European technology infrastructures. Complementing his daily work, he enjoys contributing to several scientific advisory boards of start-up enterpreneurs, multinational companies, diagnostic organisations and conference organisers, and is part of editorial boards of several scientific journals.

Personal prizes & awards

• "Netherlands X-omics Initiative", National large scale research infrastructure (NWO, 2018-2028, €40.000k)
• "EATRIS-Plus", 'Consolidating the capacities of EATRIS-ERIC for Personalised Medicine' (H2020 INFRADEV, 2020-2023, €4.900k)
• "EnFORCE", 'Enabling Functional Omics in Routine Clinical Environments' (Health Holland, 2021-2025, €1.007k)
• "CliniMARK", 'Good biomarker practice' to increase the number of clinically validated biomarkers', (COST-action, 2017-2021, €750k)
• "PERFORM", 'Personalised Risk assessment in febrile illness to optimise real-life management across the European Union' (EU H2020, 2016-2020, €1.500k)
• "Biomarker Development Centre" (STW Perspectief, 2013-2017, €4.300k)
• "CarTarDis", 'Identification and validation of new pharmaceutical drug targets for cardiovacular disease (EU FP7, 2013-2017, €4.600k)
• 'The CSV-proteome / metabolome as primary biomarker compartment for neuronal disorders' (Top Institute Pharma, 2006-2011, €800k)